Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2000

View Archived Issues

Avant Immunotherapeutics to acquire Megan Health

Favorable pharmacokinetic and tolerability profile for Angiozyme in humans

Repligen reports update on product development programs

VX-175 enters series of phase III trials

Dusa moves Levulan into phase I/II for the treatment of acne

TP-10 undergoes phase II evaluation in adult cardiac surgery patients

NicOx's HCT-1026 shows promise for treatment of skin inflammation

Virax's HIV vaccine VIR-201 approved for human study

Company Profile: EpiCept

Acadia succeeds in designing selective 5-HT2A inverse agonists/antagonists based on spiperone

Yamanouchi discovers novel class of potent, nonsteroidal human 5alpha-reductase inhibitors

Phytomedicine continues to show promise for GI inflammatory conditions

Synthetic immunomodulatory peptide inhibits production of proinflammatory cytokines in CD

PK-11195 is able to sensitize cholangiocarcinoma cells to radiation-induced apoptosis

Immediate withdrawal of Lotronex in U.S. announced by Glaxo Wellcome

Amarin licenses U.S. rights to LAX-101 for Huntington's disease

8th UEGW news: alendronate is safe and effective for increasing BMD in Crohn's disease

Fampridine-SR enters phase II trials for MS

Successful completion of Alkermes' first clinical trial with inhaled insulin

Enhanced expression of p21 associated with responses to rAd-p53 gene therapy in NSCLC

Anticoagulants targeting thrombin developed at ADIR

Novel series of cognition enhancers claimed in recent patent by ADIR

Fujisawa synthesizes cyclic hexapeptides with broad-spectrum antifungal activity

Piperidine-based renin inhibitors and their use described by Roche

Integrin alpha4beta1 inhibitors disclosed by AstraZeneca scientists

Tri- and di-aryl acid PPAR modulators claimed by Aventis for diabetes and related disorders

Lyotropic Therapeutics and Elan establish alliance for development of unique drug delivery system

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.